Lajos Pusztai, MD, DPhil, Yale School of Medicine, New Haven, CT, comments on the future of RSClin N+ in the clinic for detecting recurrence of lymph node-positive breast cancer in both pre-menopausal and post-menopausal women. Designed to be complimentary to RSClin with the lymph node-negative tool, RSClin N+ is proven to be more accurate and informative than the recurrence variable alone. The tool enables the calculation of chemotherapy-induced risk reduction, thereby enhancing patient-centered care by allowing patients to articulate their desired level of risk reduction that is feasible. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть